Cardiometabolic & kidneyCross-sectional study
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
- Serial cross-sectional study
- nationally representative
- National Health and Nutrition Examination Survey (NHANES)
Authors' conclusion
This cohort study found that CRM multimorbidity is increasingly common and undertreated among US adults, highlighting the importance of collaborative and comprehensive management strategies.
Study context
- Population
- Nonpregnant US adults (≥20 years), NHANES January 2015–March 2020; trends vs 1999–2002
- Participants
- 11,607 adults
- Outcome
- Proportion with cardiac, renal and metabolic (CRM) conditions (CVD, CKD, T2D, or all 3), overall and by age
Main finding
As reported in the abstract
CRM conditions, 2015–March 2020
- ≥1 cardiac, renal, and metabolic (CRM) condition
- 26.3%
- ≥2 CRM conditions
- 8.0%
- 3 CRM conditions
- 1.5%
- Chronic kidney disease (CKD) + T2D (most common dyad)
- 3.2%
- Cardiovascular disease (CVD) + T2D
- 1.7%
- CVD + CKD
- 1.6%
Observational data: associations, not effects.
Further findings
CRM conditions, age ≥65 years (subgroup)
- 1 CRM condition
- 33.6%
- 2 CRM conditions
- 17.1%
- 3 CRM conditions
- 5.0%
- CKD + T2D
- 7.3%
- CVD + CKD
- 6.0%
- CVD + T2D
- 3.8%
Treatment among those with 3 CRM conditions
- No reported statin use
- 30.5%
- GLP-1 receptor agonist use
- 4.8%
- SGLT2 inhibitor use
- 3.0%
Trend 1999 to 2020
- Multiple CRM conditions, from 5.3% to 8.0%
- P < 0.001 for trend
- All 3 CRM conditions, 0.7% to 1.5%
- P < 0.001 for trend
Correlates of CRM burden
- Higher burden more likely older and male; disproportionately high with non-Hispanic Black race or ethnicity, unemployment, low socioeconomic status, no high school degree
Original publication
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020. JAMA Cardiol. Published 1 November 2023. doi:10.1001/jamacardio.2023.3241
Summarised from the published abstract; every number is checked against it